Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Cash from Financing Activities data on record, last reported at $405.9 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1042.63% year-over-year to $405.9 million; the TTM value through Dec 2025 reached $426.7 million, down 6.77%, while the annual FY2025 figure was $426.7 million, 6.77% down from the prior year.
  • Cash from Financing Activities reached $405.9 million in Q4 2025 per VRDN's latest filing, up from $10.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $405.9 million in Q4 2025 and bottomed at $108000.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $77.9 million, with a median of $10.0 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: tumbled 99.78% in 2021, then soared 15202.35% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $170000.0 in 2021, then skyrocketed by 15202.35% to $26.0 million in 2022, then soared by 664.75% to $198.9 million in 2023, then tumbled by 82.14% to $35.5 million in 2024, then soared by 1042.63% to $405.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $405.9 million in Q4 2025, $10.9 million in Q3 2025, and $764000.0 in Q2 2025.